NCT02265913已完成3 期
Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Padagis LLC
- 入组人数
- 4,076
- 试验地点
- 1
- 主要终点
- Lesion Healing
研究概览
简要总结
To compare safety and efficacy of Perrigo's antiviral drug product compared to an FDA approved antiviral drug product in the treatment of cold sores.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provides written informed consent/assent
- •Immunocompetent male or non-pregnant females, >12 years old, with limited, non-life-threatening, recurrent herpes simplex labialis.
- •Subjects must have at least 3 recurrences of herpes simplex labialis per year for the past two years.
- •Females of childbearing potential willing to use an acceptable form of birth control.
- •Subjects must be in general good health with no clinically significant disease that might interfere with the study evaluations in the opinion of the investigator.
- •Subjects must be willing and able to understand and comply with the requirements of the study.
排除标准
- •Females who are pregnant or nursing, are not using or does not agree to use an acceptable form of contraception during the study, or who intends to become pregnant during the study.
- •The use of antiviral therapies in various forms for a given period of time prior to screening and study medication application.
- •Candidate for or previous use of parenteral antiviral treatment or prophylactic antiviral therapy for their recurrent herpes simplex labialis.
- •Recently received an organ transplant.
- •Subjects who are immunocompromised, HIV positive or who have any immune-system disorders.
- •Recent major change in immune system status that could seriously affect the clinical manifestations of herpes simplex labialis and need for treatment in the opinion of the investigator.
- •Subjects with known or suspected history of a clinically significant systemic disease, unstable medical disorders, life-threatening disease or current malignancies.
- •Subjects with a current episode of herpes simplex labialis that has not completely healed.
- •Presence of any facial skin condition or excessive facial hair that may interfere with diagnosis, assessment, and/or healing ability.
- •History of herpes keratitis.
- •Subject has a history of hypersensitivity or allergy to any ingredient in the drug product.
- •History of unresponsiveness to topical acyclovir therapy.
- •Participation in any other clinical study or who have received treatment with any investigational drug or device within 30 days prior to screening.
- •Subjects who have previously enrolled in this study.
- •Subjects who have received any local medication in the target area during the 2 weeks prior to both enrollment/screening and Day 1 (Visit 2).
- •Subjects who have been treated with immunosuppressive medication therapy within 8 weeks prior to the study both enrollment/screening and Day 1 (Visit 2).
- •Subject consumes excessive alcohol, abuses drugs, or has a condition that could compromise the subject's ability to comply with study requirements in the investigator's opinion.
- •Use of tanning booths, sun lamps, or excessive exposure to the sun for up to 21 days from initiating study medication
- •Subjects using immunostimulators, dye-light therapy, or psoralen therapy within 30 days prior to study medication initiation
研究组 & 干预措施
Test Product
Experimental
acyclovir cream
干预措施: Acyclovir 5 percent (Perrigo) (Drug)
Reference Product
Active Comparator
acyclovir cream
干预措施: Acyclovir 5 percent (Reference) (Drug)
Placebo Product
Placebo Comparator
Placebo cream
干预措施: Placebo cream (Drug)
结局指标
主要结局
Lesion Healing
时间窗: up to 21 days
Time to complete healing of lesions measured in hours from the time of first dosing
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal AtrophyAtrophyNCT02770365Padagis LLC695
已完成
3 期
Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne VulgarisAcneNCT02515305Padagis LLC890
已完成
3 期
Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of RosaceaRosaceaNCT02795117Padagis LLC486
已完成
3 期
To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin LesionsSecondarily Infected Traumatic Skin LesionsNCT04155203Padagis LLC657
已完成
3 期
Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the FaceAcne VulgarisNCT03393494Padagis LLC825